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Simple Summary: In mammals, different diseases are associated with intestinal changes that may cause
an increase in gut permeability. Intestinal permeability tests allow the evaluation of intestinal damage
in humans, veterinary patients and laboratory animal models. When used in mouse models, these tests
require that animals are singly housed in metabolic cages with a wire-grid floor to collect urine samples.
This raises welfare concerns. Iohexol meets several criteria for an ideal intestinal permeability marker and
has recently been used in several species. Here, we examined the performance of an intestinal permeability
test using iohexol administered by mouth and following excretion over 24 h in urine. As a model, we chose
immunodeficient mice with intestinal inflammation induced by adoptive transfer of effector/memory T
cells. We collected urine samples at seven time points to profile the urinary excretion of iohexol, in addition
to intestinal tissue samples for histological assessment. We conclude that a 6 h cumulative urine sample
may be sufficient to evaluate small intestinal permeability in this mouse model and increased urinary
excretion of iohexol is correlated with increased severity of duodenitis. The welfare of mice housed in
metabolic cages could be improved by reducing the cage periods from 24 to 6 h.
Abstract: Intestinal permeability (IP) tests are used to assess intestinal damage in patients and
research models. The probe iohexol has shown advantages compared to 51Cr-EDTA or absorbable/
nonabsorbable sugars. During IP tests, animals are housed in metabolic cages (MCs) to collect urine.
We examined the performance of an iohexol IP test in mice. Rag1-/- (C57BL/6) mice of both sexes
were divided into controls or treatment groups, the latter receiving injections of effector/memory T
cells to induce intestinal inflammation. After two, four and five weeks (W), a single dose of iohexol
was orally administered. Urine was collected seven times over 24 h in MCs. Iohexol concentration was
measured by ELISA. Intestinal histological damage was scored in duodenal sections. In control and
treated mice of both sexes, urinary excretion of iohexol peaked at 4 h. From W2 to W4/W5, urinary
iohexol excretion increased in treated mice of both sexes, consistent with development of duodenitis in
this model. Positive correlations were observed between the urinary excretion of iohexol in W4/W5
and the histological severity of duodenitis in treated male mice. We conclude that a 6 h cumulative
urine sample appears sufficient to evaluate small IP to iohexol in this mouse model, improving animal
welfare by reducing cage periods.
Keywords: duodenitis; inflammation; intestinal permeability; iohexol; metabolic cage; mouse;
permeability testing; small intestine
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1. Introduction
Intestinal permeability (IP) tests are valuable diagnostic tools to screen, monitor and
evaluate hyperpermeability and the degree of damage to the intestinal barrier in humans,
veterinary patients and experimental in vivo models [1–6]. However, animal models and
standardized IP testing protocols still need improvement, especially to further investigate
disease etiology and pathophysiology, test the effect of therapeutic agents and reduce data
variation across studies and gain consistency in the probes used [4,7,8]. Challenges in the
standardization of IP tests concern the choice of markers, variations in the procedure and
the method of sampling [9].
Chromium 51-labeled ethylenediaminetetraacetic acid (51Cr-EDTA) and/or a com-
bination of mono- and disaccharides (e.g., mannitol and lactulose) have been defined as
the gold standard to test IP over the past years [10]. Disadvantages mainly associated
with the radioactivity of 51Cr-EDTA and the bacterial degradation of the sugars have led
to the search for more appropriate candidates [4,10,11]. Iohexol, a nonradioactive, stable,
water-soluble, radiographic contrast medium, has been successfully used as an IP marker
in humans and various animal species [3,12–20]. Iohexol is not metabolized, resulting in
superior stability compared to other agents [19]. Samples containing this contrast agent
may be safely (re-)analyzed if required without any apparent degradation of iohexol [21,22].
The concentration of iohexol in very small samples of both urine and blood has been suc-
cessfully measured by using an enzyme-linked immunosorbent assay (ELISA) in different
species [2,3,16,23].
Intestinal permeability testing has not yet been widely applied in mice [8]. Serial
blood sampling for longitudinal studies in mice is invasive and subject to practical lim-
itations. Thus far, IP methods have more frequently relied on single or terminal blood
sampling during the final stage of studies [24]. Most IP tests are considered less invasive if
mouse urine is used instead. This allows the reuse and retesting of animals throughout a
longitudinal study. More recently, an iohexol IP test has been adapted for use in a coeliac
disease mouse model [23]. However, the use of specific equipment such as metabolic cages
(MCs) is required to accurately collect urine specimens, usually during a 24 h (h) period [4].
Mice must be singly housed on wire-mesh floors without bedding or enrichment [25–28].
These isolating cages are known to induce animal stress, which may lead to significant
behavioral and physiological changes and compromise animal welfare. Mice have been
shown to adapt poorly to MCs, requiring three to four days to reach equilibrium [29,30].
For all these reasons combined, IP tests in mice are rarely used in practice.
The overall objective of this study was to (1) analyze the performance of an iohexol
IP test in a mouse model of small intestinal and colonic inflammation [31], (2) determine
the time course of urinary excretion of iohexol in mice and (3) optimize the procedure
from an animal welfare perspective. Our main hypothesis was that animals with intestinal
inflammatory damage have increased IP to iohexol compared to treatment-naïve mice
and that IP increases with the development of duodenitis over time. Another hypothesis
was that IP might be assessed within a shorter period than the commonly used 24 h MC
housing after the oral administration of iohexol.
2. Materials and Methods
2.1. Study Approval
The study was planned according to ARRIVE guidelines and was approved
by the animal research board of the Southern Finnish State Administrative Agency
(ESAVI/1286/04.10.07/2016 and ESAVI/8249/04.10.07/2015).
2.2. Animals and Housing
The experiments were performed in Rag1-/- recipient mice (C57BL/6J genetic back-
ground; 12–14 weeks of age; males and females). C57BL/6J wildtype mice were used as
T cell donors (10–24 weeks of age; males and females). All mice were bred and raised
under specific pathogen-free (SPF) conditions in colonies maintained at the Laboratory
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Animal Centre (LAC) on the Viikki campus of the University of Helsinki, Finland. Breed-
ers had originally been purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
New animals are only introduced into this unit by rederivation or from certified commer-
cial breeders. Experimental mice were transferred to a conventional unit on the Meilahti
campus of the university to conduct all the experiments. The health of both units is reg-
ularly monitored by undertaking annual tests for all FELASA-listed pathogens [32,33]
as well as quarterly serological and bacteriological tests. While the facility on the Viikki
campus was negative for all tested pathogens, mouse norovirus, Staphylococcus aureus (by
culture, no lesions) and Helicobacter spp. (not H. bilis, H.hepaticus or H. rodentium) were
identified in sentinel animals of the conventional unit on the Meilahti campus during
routine health monitoring.
All mice were kept under a 14:10 h light–dark cycle (lights on at 06:00 and off at 20:00)
at 22 ± 2 ◦C and 50–60% humidity. Animals had ad libitum access to either a gluten-
free standard diet (AIN-76A) or a similar diet containing 2.5 g of wheat gluten (Sigma)
per kg (modified from AIN-76A; both diets produced and irradiation-sterilized at Research
Diets, New Brunswick, NJ, USA). Filtered tap water was provided without restrictions in
polycarbonate bottles, and the cages were cleaned once per week. Mice were housed in
individually ventilated plastic cages (Mouse IVC Green Line, 391 × 199 × 160 mm, floor
area 501 cm2; Tecniplast, Buguggiate, Italy), with half of the cage covered by a wire bar food
hopper. Aspen wood chips were provided as bedding (5 × 5 × 1 mm; Tapvei Oy, Kaavi,
Finland), along with red polycarbonate mouse igloos and Aspen wood wools (Datesand
Group and Tapvei Oy) for environmental enrichment and nesting material. A maximum of
five mice were housed per cage.
Animals were weighed twice weekly by the same experimenter at the same time over
the length of the study. Stool consistency and appearance were visually monitored for the
duration of the study and the presence of watery feces or diarrhea was noted. The animal
physical examination consisted of visual inspection of the animals’ posture, appearance
and spontaneous behavior, including symptoms of potential pain and/or distress, e.g.,
piloerection, an unkempt coat/rough hair, a hunched posture and apathy [34,35]. Mice were
routinely handled during the procedures by using a tunnel or cupped hand to avoid picking
them up by the base of the tail. Tail handling has been shown to induce aversion and high
anxiety levels that can compromise animal welfare and affect the scientific outcomes [36].
2.3. Experimental Design and Procedures
2.3.1. Time Points of Iohexol Measures
Thirty-five (17♀, 18♂) Rag1-/- mice, ranging in body weight from 24.3 to 30.6 g
in males and 16.4 to 20.9 g in females, were used in this study. Eleven mice (5♀, 6♂)
were allocated to the control group and the remaining twenty-four mice (12♀, 12♂) to the
treatment group. The sample size calculation was based on previous publications using
iohexol as a marker of IP [1,3,16,23].
After the induction of intestinal inflammation in treated mice (Week 0; Section 2.3.2),
a total of eight IP tests were performed over seven consecutive weeks (Figure 1). All‘mice
were acclimatized one week before beginning the T cell administration (Week 1). In Weeks
1 and 7 (W1 and W7, i.e., at the beginning and end of the IP study), all the untreated control
female and male mice (n = 11) were IP tested. In Weeks 2, 4 and 5 (W2, W4 and W5), the
treated mice (n = 12; n = 11 in W5) were all tested. The recovery period between the IP test in
W2 and W4 was 14 days, while that between W4 and W5 was 7 days. For the control group,
the recovery period between the IP test in W1 and W7 was 6 weeks. During W5 (treated
mice) and W7 (control mice), all mice were euthanized. The mice were exsanguinated
under ketamine–xylazine anesthesia, and tissue samples were collected for histological
assessment (see below).
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Figure 1. Study design. IP, intestinal permeability; MC, metabolic cage.
2.3.2. Induction of intestinal Infla mation
Intestinal inflammation was induced in Rag1-/- recipients by intraperitoneal injection
of 4.5 × 105 fractionated, sex-matched, splenic CD4+CD62L-CD44 high effector/memory
T cells from C57BL/6J donors in 400 µL of PBS (treated Rag1-/- mice; Figure 1) [31,37].
This model is characterized by T-cell-mediated duodenitis, enteritis and colitis. Typically,
treated Rag1-/- mice present with weight loss and diarrhea, starting 4 weeks from the
injection of T cells.
2.3.3. Treatment of Adoptive T Cell Recipient Mice with Different Diets
Immediately following adoptive T cell transfer, two subgroups of treated mice received
either a gluten-free (n = 6 female + 6 male mice) or gluten-containing (n = 6 female + 6 male
mice) diet until the end of the study (for a diet composition, see Section 2.2). Our intention
initially was to study differences in duodenitis severity induced by diet modification.
Because our study remained underpowere to perform this comparison, based on previo s
experie ce [31,37,38], we decided to pool both treated subgroups for analysis. Below, we
refer to both subgroups as “treated mice.” Untreated control mice were maintained on a
gluten-free diet throughout the study.
2.3.4. Measurement of Intestinal Permeability
The iohexol IP test consisted of a single dose of iohexol (10 mL/kg, 647.1 mg/mL,
Omnipaque 300®, Amersham Health, The Netherlands) administered by orogastric gavage
to each mouse using a malleable stainless steel feeding needle and a 1 mL syringe [23].
The recommended iohexol dosage for the assessment of intestinal permeability in mice was
adjusted from Frias et al. [1]. After iohexol dosing, the animals were placed in individual
MCs for urine collection for 24 h. Urine samples were taken seven times over 24 h (at 2, 4, 6,
12, 15, 18 and 24 h), starting when the lights turned off in the animal room (Figure 2). This
moment is the beginning of the active phase of the circadian rhythm of the mice [39–41].
During this phase, a dim red light was used to maintain the circadian organization and to
avoid any circadian disturbance in the animals during the experiment [42–44]. No sedative
drug was used before, during or after iohexol administration. Animals were randomly
oral-dosed and allocated to each MC by using a list randomizer program (https://www.
random.org/lists/). Three food pellets and bottles of fresh tap water were provided before
using the MCs.
The volume of recovered urine was individually recorded, and urine samples were
kept in Eppendorf tubes and frozen at −20 ◦C. If fecal contamination of urine was observed,
the affected sample was discarded.
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Figure 2. Timeline for the metabolic cage housing and urine sampling. MC, metabolic cage.
2.3.5. Iohexol Measurement
The iohexol concentration in mouse urine was determined by ELISA according to the
manufacturer’s instructions (FIT–GFRTM Iohexol Kit, BioPAL Inc., Worcester, MA, USA)
and also as described by Ortín-Piqueras et al. [2]. Before analysis, urine samples were
brought to room temperature and thoroughly mixed. All samples were analyzed in
duplicate to increase the reliability of the analysis. The urinary excretion of iohexol (% of
ingested i ex l) in mice was calculated si g the following equation [1,3,16]:
Iohexol in urine (%) = amount of iohexol excreted in urine after each time period (mg)amount of administered iohexol (mg) × 100.
(1) =
concentration of iohexol in urine (mgmL )× DF × TUV (mL)
volume of iohexol given orally (mL) x concentration of iohexol solution (mgmL )
× 100
DF, dilution factor; TUV, total urine volume recovered within certain hours
2.3.6. Tissue Collection and Histological Score for Duodenitis
Mice were exsanguinated under ketamine/xylazine anesthesia after either 5 or 7
weeks (see Figure 1). The weight of the entire small intestine, duodenum (2 cm) and
colon was recorded (weights including bowel content). For the histological assessment,
duodenal samples were fixed in formalin and embedded in paraffin, and longitudinal
sections (6 µm) were stained with hematoxylin and eosin (H/E). To identify proliferating
cells in additional sections, the Lab Vision PT Module (Thermo Fisher, Waltham, MA, USA)
was used. For antigen retrieval, sections were immersed in TRIS-HCl, pH 8.5, prewarmed
to 65 ◦C for 30 min, and treated at 98 ◦C for 30 min. Sections were stained using polyclonal
rabbit anti-mouse Ki-67 IgG (dilution 1:500, incubation at RT for 1 h; Bethyl Laboratories),
peroxidase blocking (incubation 15 min), biotinylated goat anti-rabbit IgG, avidin–biotin
complex reagent (incubation both for 30 min) and diaminobenzidine substrate (incubation
for 10 min; all from Vector Laboratories). Hematoxylin (incubation for 45 s) was used for
counterstaining. The histological score for duodenitis was assessed in a blinded fashion
in well-oriented sections and at sites representative of maximal damage, as reported
previously [38]. The length of 5 crypts (stained epithelial cells) and 5 villi (unstained
epithelial cells) was measured in duodenal sections stained for Ki-67, and villus/crypt
architecture scores were assigned as follows: score 0 (V/C ratio > 3.00), 0.5 (2.50–3.00),
1.0 (2.00–2.49), 1.5 (1.50–1.99), 2.0 (1.00–1.49), 2.5 (0.50–0.99), 3.0 (<0.5). Villus cellular
infiltration was graded in H/E-sections as follows, assessing 5 villus/crypts units: score
0 (villus lamina propria diameter < 0.5 × crypt diameter), 1 (0.5–1×), 2 (1–2×), 3 (>2×).
Basal infiltration with neutrophils was graded in H/E-sections as follows: score 0 (normal
crypts), 1 (1–7 crypt abscess(s) per duodenal section), 2 (8–15 crypt abscesses), 3 (>15 crypt
abscesses). Each specimen was assigned a composite histological score for duodenitis by
combining the above three separate parameters (maximum score: 3 + 3 + 3 = 9).
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2.4. Statistical Analysis
All statistical analyses were performed and graphs were drawn with SPSS (IBM SPSS
26.0, SPSS Inc., Chicago, IL, USA) and GraphPad Prism (GraphPad Prism 8, GraphPad
Software Inc., San Diego, CA, USA), respectively. The model fit was assessed by eval-
uating studentized model residuals graphically (normal QQ plot) and with histograms
and by a test of normality (Kolmogorov–Smirnov). Decimal logarithm (Log10 (1 + x))
transformation was used for the urinary excretion of iohexol to satisfy the normality as-
sumption. Differences in the number of animals delivering urine, the volume of urine,
animal body weight and urinary excretion of iohexol were analyzed using either the
Mann–Whitney U-test or t-test to calculate statistical differences between two independent
variables or Kruskal–Wallis or one-way ANOVA for more than two variables. Post hoc
tests were applied for multiple comparisons with Bonferroni correction. A linear mixed
model test was performed to analyze the interaction between fixed effects described as
follows: group (control and treatment), urine analysis time point (2, 4, 6, 12, 15, 18 and
24 h), sex (female and male) or treatment effect analysis week (W1, W2, W4, W5 and W7)
with two-way interactions of each independent variable. The results were expressed as
the median ± interquartile range (±IQR) or mean ± standard deviation (±SD). All corre-
lations were calculated by using Spearman’s rank correlation coefficient (r). Values of
p < 0.05 were considered statistically significant.
3. Results
3.1. Clinical Examination
Body weight, fecal consistency and the health condition of the animals were monitored
throughout the study. During each IP testing session, animal behavior was observed.
Overall, the mice were in good physical condition and behaved normally. They displayed
normal behavior after returning to their home cages from the MCs. Only one male mouse
from the treated group was removed during the running IP test in W5. This animal
displayed changes in behavior, i.e., apathy, rough hair coat and hunched posture, at the
start of the experiment and was excluded from W5 iohexol analysis.
The stool consistency for all mice was mostly reported as normal. Occasional transient
wet or pasty stools were observed in W4 or W5, respectively, in some female and male mice
from the treatment group. These changes in stool consistency were only obvious by visual
observation during MC housing. One urine sample was discarded from iohexol analysis
due to fecal contamination.
The median ± IQR weight for control and treated female mice was 19.15 g ± 1.10 and
20.00 g ± 1.10, respectively, and for control and treated male mice it was 29.10 g ± 1.90
and 24.70 g ± 1.40, respectively. The weight curve for the entire study and the changes in
body weight after each period of MC housing are presented in Figure S1. In both female
and male mice, there was a significant difference in the median ± IQR weight between the
control and treatment groups (p < 0.001). In control and treated male mice, there were some
drops in body weight immediately after the IP test in MC housing without any significant
difference (Figure S1).
3.2. Number of Animals Delivering Urine and Volume of Collected Urine
The median ± IQR number of control (n = 11) and treated mice (n = 12) that urinated
during the cumulative seven time points over the 24 h period is illustrated in Figure S2.
The median ± IQR number of control mice that urinated during the IP tests (cumulative
hours) was 2.00 ± 0.00 (2 h), 8.50 ± 3.00 (4 h), 10.50 ± 1.00 (6 h) and 11.00 ± 0.00 (12–14 h),
respectively (Figure S2). The median ± IQR number of treated mice was 3.50 ± 0.50
(2 h), 9.50 ± 0.50 (4 h) and 12.00 ± 0.50 (6–24 h), respectively (Figure S2). In total, the
median ± IQR number of animals delivering urine was 3.00 ± 2.00 (2 h), 9.50 ± 2.00
(4 h), 11.50 ± 1.50 (6 h), 12.00 ± 1.00 (12 h), 12.00 ± 1.00 (15 h), 12.00 ± 1.00 (18 h) and
12.00 ± 1.00 (24 h), respectively. This represents 25% (2 h), 79.2% (4 h), 95.8% (6 h) and
100% (12–24 h) of all mice.
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The total volume (µL) of mouse urine collected during the IP tests is presented in
Figure S3 and Table S1. In treated and control mice, the volume of urine peaked at 4 h,
followed by a less pronounced increase at 24 h. In control mice in W1, the first peak in
urine volume was at 2 h. The median ± IQR volume of urine in control mice in W1 and W7,
and in treated mice in W2, W4 and W5 was 108.00 ± 240.00, 48.00 ± 169.99, 60.00 ± 96.50,
55.00 ± 74.75 and 54.5 ± 77.00 µL, respectively. There was a significant difference in the
volume of mouse urine collected during the IP tests between control and treated mice
(p = 0.014), and more specifically between W1 and W2 (p = 0.022), W1 and W4 (p = 0.019)
and W1 and W5 (p = 0.001).
3.3. Urinary Excretion of Iohexol during 24 h
The urinary excretion of iohexol was examined by determining the percentage of orally
administered iohexol recovered in mouse urine (Figure 3, Table S2). When combining the
data from all measurement time points during the study, there was no significant difference
in the urinary excretion of iohexol between all treated and control mice (p = 0.223). Data
analysis revealed a significant difference in the urinary excretion of iohexol (%) between the
treatment groups in W4 and W5 compared to that in W2 (p < 0.001) (Figure 3A). There was
also a significant difference in the urinary excretion of iohexol when comparing both control
mice (W1 and W7) and treated mice in W2 with treated mice in W4 and W5 (Figure 3B).
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Figure 3. Urinary excretion of iohexol (%) during 24 h following oral administration in all mice (A,B) and (C) female and
(D) male mice over 24 h, with data combined for the 7 weeks of intestinal permeability testing. Data are presented on a
base-10 log scale (Log10 (1 + x)). The horizontal line in the box is the median (50% percentile), and the upper and lower
limits of the box indicate the 75% upper and 25% lower quartiles, respectively. The limits of the upper and lower vertical
lines represent the maximum and mini u data results, respectively. t sent each of the s ven urinary collection
time points during the 24 period. * p < 0.05, ** p < 0.01, *** p < 0.001.
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When combining the data from all measurement time points during the study,
there was no significant difference in the urinary excretion of iohexol between male
and female mice (p = 0.532). In female mice, there was a significant difference in the
urinary excretion of iohexol between treated mice in W2 and W4 (p = 0.048) and W2
and W5 (p = 0.002) and between control mice in W7 and treated mice in W5 (p = 0.033)
(Figure 3C, Table S3). In male mice, a significant difference in the urinary excretion of
iohexol occurred in treated mice between W2 and W4 (p < 0.001) as well as between
W2 and W5 (p < 0.001) (Figure 3D, Table S3).
In control and treated mice, there was a significant difference in the urinary excretion
of iohexol between the seven urinary collection time points (p < 0.001). In both treated and
control mice, the urinary excretion of iohexol peaked at 4 h. There was also a second and
less pronounced increase at 24 h in control mice and in treated mice only when IP was
tested in W4 and W5 (Figure 4A,B, Table 1 and Table S4). These increases in the urinary
excretion of iohexol at 4 h and 24 h were higher in the treated mice in W4 and W5 than
in the treated mice in W2 and the control mice. At 4 and 24 h, the strongest significant
differences in the urinary excretion of iohexol occurred between W2 and W4 (p = 0.003,
p = 0.007, respectively) and W2 and W5 (p < 0.001, p = 0.002, respectively). Unfortunately,
at the 2 h time point, there were too few pairs of urine samples to obtain a meaningful
result (n = 3/23 in control mice in W1 and W7, and n = 19/71 in treated mice in W2, W4 and
W5). The urinary excretion of iohexol (%) in female and male mice, measured seven times
(at 2, 4, 6, 12, 15, 18 and 24 h) over 24 h after oral administration of iohexol, is presented
in Figure 4C,D.
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Figure 4. Urinary excretion of iohexol (%) in control and treated (A) female (C) and male (D) mice at seven separate
urine collection time points or (B) at seven cumulative time points (after 2, 4, 6, 12, 15, 18 and 24 h) over 24 h after oral
administration of iohexol. Data are shown on a base-10 log scale (Log10 (1 + x)) and expressed as means ± SD. * p < 0.05,
*** p < 0.001.
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3.4. Correlation between the Urinary Excretion of Iohexol Measured at Seven Time Points and in
Cumulative Urinary Samples over a 24 h Period in Mice
Table 2 presents the correlation coefficients between the urinary excretion of iohexol
after the cumulative 24 h time point and the seven individual samples collected over 24 h
in control and treated mice, including the differences between sexes (Table S5). The sum
of the urinary excretion of iohexol (%) from two up to three individual mouse urine
samples produced a strong correlation that varied from 0.61–0.74, while from four up to six
individual mouse urine samples combined produced a very strong correlation that varied
from 0.84–0.88. Likewise, the correlation coefficients were strong between the urinary
excretion of iohexol after the cumulative 24 h period and the individual mouse urine
samples collected 2 h and 24 h after oral iohexol administration.
Table 2. Correlation coefficients between the urinary excretion of iohexol in both the seven individual and the cumulative
urinary collection samples, collected during 24 h after the oral administration of iohexol to control (W1 and W7; total n = 22)













(0–24 h) 2 h 4 h 6 h 12 h 15 h 18 h 24 h 2 + 4 h 2 + 4 + 6 h
2 + 4 + 6
+ 12 h
2 + 4 + 6 +
12 + 15 h
2 + 3 + 4
+ 6 + 12 +
15 + 18 h
Correlation
coefficient 0.76 0.58 0.48 0.54 0.55 0.59 0.66 0.61 0.74 0.84 0.84 0.88
n, number
of mice 22 73 77 77 47 63 73 74 91 93 93 93
p-value *** *** *** *** *** *** *** *** *** *** *** ***
Correlations were calculated using Spearman’s rank coefficients where appropriate. Significance levels are expressed as: *** p < 0.001.
3.5. Correlation between the Histological Score for Duodenitis and the Weight of the Duodenum or
Total Small Intestine
Histological duodenitis was assessed, as reported previously [38], also demonstrated
in Table S6. Ki–67–stained histological sections representing different duodenitis severity
scores are demonstrated in Figure 5. The correlation between the histological score for
duodenitis and the weight of the duodenum or the total small intestine is illustrated
in Figure 6 and presented in Table S7. A strong correlation coefficient was obtained
between the histological score for duodenitis and the duodenum weight in female and
male mice together and separately (Spearman’s rho: n = 0.76, p < 0.001, n = 27; 0.60, p = 0.020,
n = 15; 0.71, p = 0.004, n = 15, respectively). The correlation between the histological score of
duodenitis and the ratio of the duodenum or the total small intestine weight to animal body
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weight is presented in Table S8. A strong correlation coefficient was obtained between the
histological score of duodenitis and the ratio of duodenum weight to animal body weight
in female and male mice together and separately (Spearman’s rho: n = 0.73, p < 0.001,
n = 27; 0.70, p = 0.005, n = 15; 0.77, p = 0.001, n = 15, respectively). Data on the duodenum
weight were obtained from a group of control mice (n = 3) for comparison.
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Figure 6. Spearman’s rank correlation coefficient between the histological score for duodenitis and the weight of (A) the
duodenum and (B) the total small intestin in treated and control mice combined.
3.6. Correlation between Urinary Excretion of Iohexol and the Histological Score for Duodenitis or
the Weight of the Duodenum o Total Small Intestine
Th correlation between the cumul tive uri ary excretion of iohexol in W4 and W5
and the histological score for duodenitis is prese ted in Figure 6. IP tests were performed
in W4 and W5 of treatment, by which time the intestine is affected by T-cell-mediate
inflammation in this model. The urinary excretion of iohexol in W4 and W5 is therefore
more likely to reflect the histological assessment than W2. In treated male mice, there was
a positive correlation between the urinary excretion of iohexol and the histological score
for duodenitis in W4 and W5. This was most evident during the early time points after
iohexol oral administration for the cumulative urine samples from 0–2, 0–4, 0–6, 0–12 and
0–15 h (Spearman’s rho: n = 0.83, p = 0.006, n = 10; 0.58, p = 0.003, n = 26; 0.55, p = 0.004,
n = 26; 0.54, p = 0.005, n = 26; 0.58, p = 0.002, n = 26, respectively) (Table S9) and was even
more obvious in treated male mice in W5 (Figure 7 and Table S9). There was also a positive
correlation between the urinary excretion of iohexol and the duodenum weight for the
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cumulative samples from 0–2, 0–12, 0–15 and 0–18 h (Spearman’s rho: n = 0.77, p = 0.014,
n = 10; 0.43, p = 0.030, n = 26; 0.41, p = 0.039, n = 26; and 0.42, p = 0.034, n = 26, respectively)
(Table S9) in treated male mice in W4 and W5 as well as in treated female mice in W4 for
the cumulative 0–2 h urine sample (Spearman’s rho: n = 0.77, p = 0.036, n = 8). There was
no correlation between the urinary excretion of iohexol and the total small intestinal weight
(Table S9) in either male or female treated mice.
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Figure 7. Spearman’s rank correlation coefficient between the histological score for duodenitis and the urinary excretion of
iohexol in time periods (A) 0–2 h, (B) 0–4 h, (C) 0–6 h, (D) 0–12 and (E) 0–15 in treated male mice in Week 5.
4. Discussion
The findings from our study support the use of iohexol as a probe for IP testing in
mice. They describe the time course of urinary excretion of iohexol during a 24 h period in
both untreated mice and mice with intestinal inflammation induced by adoptive transfer
of effector/memory T cells. In this mouse model, mice develop duodenitis, enteritis
and colitis [31,37].
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According to our results, the excretion of iohexol in urine peaks at 4 h after its oral
administration in control and treated mice, followed by a lower peak at 24 h in control mice
and only in Weeks 4 and 5 in treated mice. The number of urine samples at 2 h was too low
to obtain a meaningful result. The profile of urinary excretion of iohexol was reminiscent
of previous reports using 51Cr-EDTA as an IP marker in the serum of healthy dogs over a
6 h period [10]. IP varies along the axis of the gastrointestinal (GI) tract [45]. The iohexol IP
peak at 4 h probably reflects small intestinal permeability to iohexol. Our results provide
additional evidence that the permeation of iohexol across the intestine is greater in the first
hours after its oral administration. This may support the use of a shorter mouse IP testing
period in MCs than the common 24 h for the assessment of small intestinal permeability.
A shorter testing period would increase the practicability of the method while allowing a
reduction in the time spent by laboratory mice in the isolating MCs.
Single iohexol urinary samples produced moderate to strong correlation coefficients
with the cumulative 24 h urinary excretion of iohexol. The highest correlation coefficients
occurred when samples were taken at 2 or 24 h (r = 0.76 or r = 0.66, respectively). In control
and treated mice of both sexes, the correlation coefficients were even stronger when
comparing the cumulative 24 h urinary excretion of iohexol with the combination of single
urine samples, specifically from three up to six single urine samples taken 2, 4, 6, 12, 15 and
18 h after iohexol administration (r = 0.74–0.88; p < 0.001). It is expected that the sum of
multiple single iohexol urine samples better reflects the cumulative 24 h urinary excretion
of iohexol than only the single urine samples. The latter are measured at one point in time,
whereas the former more closely resemble the cumulative excretion of iohexol in urine.
One of the major disadvantages when using multiple collection time points in MCs is
that not all individuals urinate at every required time point. In our study, 6 and 12 h were
the time points with the highest number of animals urinating over the IP testing session. The
cumulative urine volume within the first 6 h indicated that 95.8% of the animals delivered
urine at least once during this period and 100% of mice within the first 12 h.
The use of the isolating MCs for prolonged periods (commonly 24 h) is mostly jus-
tified to allow the collection of sufficient volumes to run urinary IP tests. The volume
of urine may influence the urinary excretion of the probes [46], and it should therefore
be precisely collected and measured throughout the test. Our results demonstrated that
urinary collection from the MCs over 6 or 12 h comprised more than half (59% or 68%,
respectively) of the total median ± IQR excreted volume (0.27 or 0.31 mL out of the total
0.45 mL, respectively) over the 24 h IP test. The volume of urine that is needed to per-
form an enzyme-linked immunosorbent assay (ELISA) test normally varies from 0.010 to
0.020 mL. A 6 h MC urinary collection period may yield more than the required volume to
perform the analysis in duplicate or even triplicate. It is known that in very small urine and
blood samples from different species, the concentration of iohexol has been successfully
analyzed by using ELISA [2,3,16,23]. A study from 2018 recorded a strong correlation
between ELISA, high-performance liquid chromatography (HPLC) and neutron activation
analysis (NAA) techniques when analyzing the iohexol concentration in canine plasma [2].
While these results cannot be directly extrapolated to mouse urine and blood samples, the
same correlation between ELISA, HPLC and NAA is expected in mice.
The urinary excretion of iohexol was higher in treated than in control mice. The treated
mice showed significant differences in iohexol excretion between W2 and both W4 and W5.
This difference is consistent with the observation that the development of clinical intestinal
disease in this model requires at least four weeks, following T cell reconstitution after
homeostatic hyperproliferation of transferred T cells in lymphopenic Rag1-/- recipients,
leading to body weight loss that usually starts between Weeks 4 and 5 [31]. Although these
differences were observed in both sexes, male mice exhibited a greater increase in iohexol
excretion between W2 and W4/W5 than females. In treated mice, iohexol excretion in urine
in W4 or W5 was correlated both with the severity of histological duodenitis and weight
of the duodenum or small intestine. All these correlations were more evident in W5 than
W4 and were stronger in treated male than female mice. This was most evident during
Animals 2021, 11, 79 13 of 17
the early time points after the iohexol oral administration, with a very strong positive
correlation at 0–2 h, a strong correlation at 0–4, 0–6 and 0–12 h and a moderate correlation
at 0–15 h between the urinary excretion of iohexol and the histological score for duodenitis
in treated mice in W5. In both female and male mice, there was also a strong positive
correlation between the histological score for duodenitis and the duodenum weight and
the ratio of duodenum weight to animal body weight. These findings suggest that the use
of iohexol for measuring increased permeability as a result of intestinal inflammation in
mice is feasible.
Under visual examination, our mice from both groups (control and treated) were in
good physical condition and behaved normally over the length of the study. Only one male
mouse from the treated group was returned to its home cage during the ongoing IP test
in W5. This mouse was displaying changes in behavior, i.e., apathy and rough hair coat,
probably related to treatment. We did not include an ethogram or measurement of any of
the stress markers in mouse blood or urine, e.g., corticosterone [47].
In general, control female and male mice and treated female mice gained weight over
the length of the study to a lesser or greater degree, while treated male mice apparently
lost weight. This difference could reflect a treatment-related effect in the treated male mice.
However, the total weight loss in all animals did not even reach 5%, so the weight was still
within normal value ranges [48,49].
Stool consistency and appearance for control and treated mice were mostly graded as
normal. Occasional transient wet or pasty stools were observed in W4 or W5, respectively,
in some female and male mice from the treatment group. These changes in stool consistency
were only obvious in visual observation during MC housing and were not detected during
the weekly body weight measurement sessions. One urine sample was discarded from
iohexol analysis due to fecal contamination. Food contamination was also found in some
of the urine sample containers. This could not have influenced the iohexol analysis since
the marker was applied via gastric intubation and not with the food.
The use of 24 h MC housing is the current gold standard technique for the collection
of mouse urine samples. This method is, however, susceptible to different contaminants
such as stools or food, which may affect the results to an unknown greater or lesser degree.
Alternatives to MCs such as hydrophobic sand [50–52] are refined techniques that have not
been yet extensively used in rodents, unlike MCs. Efforts should be made to promote the
implementation of easy-to-use, noninvasive, less stressful and less variable refined devices
or methods for the collection of urine samples in rodents during IP testing.
To the best of our knowledge, the performance of a urinary iohexol IP test has never
been assessed in mice. Our main aim was to analyze the iohexol IP test method in an
inflammatory intestinal disease model. The results confirmed our hypothesis that mice
suffering from intestinal inflammation display increased iohexol IP. We also report a time
course of iohexol urinary excretion. In the future, it may be possible to assess IP in a period
shorter than 24 h, specifically within the first 6 or 12 h after oral iohexol administration.
Single housing in metabolic cages on a wire-mesh floor deprives the animals of cage
enrichment and bedding, living space and group housing. Rodents have been shown
to only acclimatize to MCs after three to four days [29,30]. All these factors are known
to compromise animal welfare, which may induce stress or discomfort in laboratory
rodents [26,30,53,54], and thus may confound the research data. Many other factors,
such as age, strain, sex, social position and housing and husbandry regimens, might also
influence research data [55]. According to the literature, prolonged stress periods are
considered to have significant consequences for animal health and welfare by changing
the physiological parameters of the reproductive, endocrine, cardiovascular, digestive and
immune systems [56–59]. Rodents can undergo stress-induced changes in the intestine
and are therefore even suggested as model animals for irritable bowel syndrome [59].
When studying the influence of inflammation on IP, it is important to keep the stress level
to a minimum to reduce its influence on intestinal function as a confounding factor in
gastrointestinal research.
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Murine models to replicate animals and human diseases are still needed to provide
basic information regarding intestinal and no intestinal diseases in humans, in vivo re-
search models or veterinary patients. These murine models have notable advantages in
terms of a large available sample size and a well-understood, genetically homogeneous
background [60]. Laboratory mice could directly benefit from the improvement and stan-
dardization of iohexol IP testing protocols.
In future studies, the excretion of iohexol in serum and plasma after oral ingestion
of the probe molecule may be compared with the urinary excretion of iohexol in mice.
Serial blood sampling in mice during IP tests is still impractical, mainly because of the
invasiveness of the technique. The information gained from the most suitable urine
sampling time point(s) can inform the methodology of blood sampling to assess iohexol IP
in mice. In future research, iohexol IP tests in rodents may be equally performed on either
urine or blood. The use of blood samples in small amounts could replace the use of MCs,
and urine collection may no longer be required for IP tests in mice.
5. Conclusions
In summary, we report on the performance of a refined permeability testing protocol
using the urinary excretion of iohexol in mice. Iohexol excretion in urine in Weeks 4 or 5
of treatment was correlated with increased severity of histological duodenitis, suggesting
that iohexol may be used as a marker to assess intestinal damage in this inflammatory
disease model. We also addressed the use of MCs to collect urine in mice and obtained
a time course of the urinary excretion of iohexol over 24 h. Urine collection within 6 h
after iohexol oral gavage may be sufficient to evaluate IP in a mouse model of intestinal
inflammation, although further studies are still warranted to validate the findings. Those
studies may confirm the value of iohexol as a diagnostic tool for the assessment of IP in
rodent species in research and clinical settings.
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